BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care

BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments, announced its intention to adopt a new English name: BeOne Medicines Ltd. The rebranding reflects the company’s mission to unite global efforts in the fight against cancer and underscores its transformative approach to fostering cross-sector collaboration.

A Vision to Eradicate Cancer

The new name, BeOne Medicines, embodies the company’s dedication to innovative drug development and its commitment to partnering with stakeholders worldwide to serve more patients. This bold vision aims to eradicate cancer through unified efforts and shared expertise across various fields.

Stock Ticker Change to ONC

In conjunction with the rebranding, BeiGene will also change its NASDAQ stock ticker symbol to ONC. This change signifies a new chapter in the company’s journey as it continues to lead the charge against cancer through groundbreaking research and collaboration.-Fineline Info & Tech

Leave a Reply

Your email address will not be published. Required fields are marked *

Fineline Info & Tech